Reglan Tardive Dyskinesia Settlement: Understanding the Statute of Limitations in Massachusetts

Latest update (2025-07)

From General Health Awareness to Specific Risk Assessment

For decades, general health and science information has served as the foundation for public understanding of medication risks and patient safety. This broad educational context has empowered individuals to recognize potential adverse effects associated with prescription drugs, particularly those used in chronic care settings. Within this legacy framework, the focus has remained on raising awareness about treatment outcomes and the importance of informed medical decision-making. As this foundational knowledge evolves, a more targeted concern emerges regarding specific pharmaceutical exposures in occupational environments. The transition from general health literacy to specialized risk assessment becomes particularly relevant when considering medications like Reglan (metoclopramide), commonly prescribed for gastrointestinal disorders. In mass production settings, workers may encounter this drug through manufacturing processes, handling, or environmental exposure, raising distinct questions about long-term safety monitoring. This shift in perspective requires careful attention to the legal and temporal boundaries that govern claims related to such exposures. In Massachusetts, the statute of limitations for Reglan-related tardive dyskinesia claims represents a critical consideration for individuals who may have been affected during their occupational activities. Understanding these time constraints is essential for those seeking to address potential health consequences arising from workplace exposure to this medication, marking a clear pivot from general health education to specific occupational risk management.

Reglan and the Risk of Tardive Dyskinesia: Medical Evidence

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved prescribing information includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and healthcare providers are advised to use the medication for the shortest duration necessary, periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks, and for diabetic gastroparesis, total treatment duration should also be avoided beyond 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The medication is not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations for Reglan Claims in Massachusetts

For individuals in Massachusetts who have developed TD after using Reglan, the statute of limitations is a critical legal consideration. The statute of limitations sets a time limit on when a lawsuit can be filed. In Massachusetts, the statute of limitations for personal injury claims, including those related to prescription drug side effects, is generally three years from the date the injury is discovered or reasonably should have been discovered. This means that affected patients must file a claim within three years of becoming aware of their TD diagnosis and its potential link to Reglan use. The timeline between exposure to Reglan and the onset of TD can vary widely, as TD may develop after months or years of use, and symptoms may be subtle initially. The FDA boxed warning emphasizes that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), so patients who used Reglan for extended periods may be at greater risk. However, TD can also occur after shorter-term use, and the prescribing information advises immediate discontinuation if symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Settlement-related considerations for affected patients include the adequacy of warnings provided by the manufacturer. The FDA-approved labeling includes a boxed warning about TD, but patients may argue that the warnings were insufficient or that they were not adequately informed of the risks before starting treatment. The prescribing information states that Reglan is contraindicated in patients with a history of TD and that use should be limited to the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, some patients may have been prescribed Reglan for longer than recommended or without proper monitoring. The risk of TD is also highlighted in the warnings and precautions section, which advises avoiding concomitant use of other drugs known to cause TD and avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient develops TD, they may be eligible for compensation through a settlement, but the statute of limitations in Massachusetts imposes a strict deadline. Patients should consult with a legal professional to determine their specific rights and the applicable time frame for filing a claim.

Summary and Next Steps

In summary, Reglan use is associated with a risk of tardive dyskinesia, a potentially irreversible movement disorder, and the FDA labeling provides clear warnings about this risk. For Massachusetts patients, the statute of limitations for filing a lawsuit is generally three years from the discovery of the injury. The timeline between Reglan exposure and TD development can vary, and patients should be aware of the need to act promptly if they suspect a link between their TD and Reglan use. Settlement considerations may involve the adequacy of warnings and the duration of treatment, as longer use increases risk. Affected individuals should seek legal advice to understand their options and ensure compliance with the statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to prescription drug side effects, is generally three years from the date the injury is discovered or reasonably should have been discovered. This means affected patients must file a claim within three years of becoming aware of their TD diagnosis and its potential link to Reglan use.

Can tardive dyskinesia develop after short-term use of Reglan?

Yes, tardive dyskinesia can occur after short-term use of Reglan, although the risk increases with longer treatment duration and higher cumulative doses. The FDA prescribing information advises immediate discontinuation if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. DailyMed - Reglan Label

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Take the first step toward compensation.

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.